Clients News • MC Services corporate website
paged,page-template-default,page,page-id-5522,paged-6,page-paged-6,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.4.2,vc_responsive




  • XPhyto adds Mescaline production to psychedelic medicine programs
  • Relief Confirms Release of Preliminary Findings from Phase 2b/3 Trial of Intravenous RLF-100™ (aviptadil)
  • Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors
  • MagForce AG: MagForce USA, Inc. Announces Completion of Patient Treatment in Stage 2a of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System
  • Secarna Pharmaceuticals: Secarna Pharmaceuticals appoints Alexander Gebauer, MD, PhD as CEO and Managing Director
  • Imcyse SA: Imcyse Enters into Research Collaboration and License Agreement for its ImotopeTM Technology with Pfizer in Rheumatoid Arthritis
  • Imcyse SA: Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
  • XPhyto announces psychedelic pharmaceutical production agreement
  • CENTOGENE GmbH: CENTOGENE eröffnet Walk-In-Corona-Testzentrum am Flughafen Köln / Bonn
  • CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP® Technology in anti-tumor cell therapies